FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Assen Dudov et al.|Annals of Oncology|2021Cited by 357
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische OnkologieS. Al-Batran, Elke Jäger, J. T. Hartmann et al.|Annals of Oncology|2008Cited by 281
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Florian Lordick, Tibor Schuster et al.|Annals of Oncology|2009Cited by 241